vaccination

Summary

Summary: Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.

Top Publications

  1. ncbi Induction of broadly neutralizing H1N1 influenza antibodies by vaccination
    Chih Jen Wei
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, Bethesda, MD 20892 3005, USA
    Science 329:1060-4. 2010
  2. ncbi Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
    Punnee Pitisuttithum
    Department of Clinical Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
    J Infect Dis 194:1661-71. 2006
  3. ncbi Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
    Jinyan Liu
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 457:87-91. 2009
  4. ncbi Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials
    Eric Plennevaux
    Clinical Development Department, Sanofi Pasteur, Lyon, France
    Lancet 375:41-8. 2010
  5. ncbi Rapid cloning of high-affinity human monoclonal antibodies against influenza virus
    Jens Wrammert
    Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Nature 453:667-71. 2008
  6. ncbi Optimizing influenza vaccine distribution
    Jan Medlock
    Epidemiology and Public Health, Yale University School of Medicine, 60 College Street, New Haven, CT 06520 8034, USA
    Science 325:1705-8. 2009
  7. ncbi Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation
    Marc Baguelin
    Centre for Infections, Health Protection Agency, United Kingdom
    Vaccine 28:2370-84. 2010
  8. ncbi Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong
    Benjamin J Cowling
    Infectious Disease Epidemiology Group, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China
    Clin Infect Dis 51:1370-9. 2010
  9. ncbi Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses
    Denis Gaucher
    Laboratoire d Immunologie, Centre de Recherche du Centre Hospitalier de l Université de Montréal CR CHUM Saint Luc, Montreal, Quebec, Canada
    J Exp Med 205:3119-31. 2008
  10. ncbi Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial
    Xiao Feng Liang
    Chinese Center for Disease Control and Prevention, Beijing, China
    Lancet 375:56-66. 2010

Research Grants

  1. Role of cyclooxygenase-2 in antibody responses to vaccination
    Richard Phipps; Fiscal Year: 2007
  2. VARIABLE GENE USE AND PNEUMOCOCCAL IMMUNITY IN AIDS
    Liise Anne Pirofski; Fiscal Year: 2004
  3. Recommendation of HPV Vaccination among U.S. Physicians
    Susan Vadaparampil; Fiscal Year: 2009
  4. Recommendation of HPV Vaccination among U.S. Physicians
    Susan T Vadaparampil; Fiscal Year: 2010
  5. Anti-Idiotype Therapy of Human B Cell Malignancy
    Ronald Levy; Fiscal Year: 2007
  6. Health Promotion Coaching/Vaccine for Homeless Parolees
    Adeline M Nyamathi; Fiscal Year: 2010
  7. Health Promotion Coaching/Vaccine for Homeless Parolees
    Adeline Nyamathi; Fiscal Year: 2009
  8. Health Promotion Coaching/Vaccine for Homeless Parolees
    Adeline M Nyamathi; Fiscal Year: 2010
  9. HIFU-enhanced tumor vaccines
    Chandan Guha; Fiscal Year: 2010
  10. HIFU-enhanced tumor vaccines
    Chandan Guha; Fiscal Year: 2010

Detail Information

Publications290 found, 100 shown here

  1. ncbi Induction of broadly neutralizing H1N1 influenza antibodies by vaccination
    Chih Jen Wei
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, Bethesda, MD 20892 3005, USA
    Science 329:1060-4. 2010
    ..Here, we show that vaccination with plasmid DNA encoding H1N1 influenza hemagglutinin (HA) and boosting with seasonal vaccine or replication-..
  2. ncbi Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
    Punnee Pitisuttithum
    Department of Clinical Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
    J Infect Dis 194:1661-71. 2006
    ....
  3. ncbi Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
    Jinyan Liu
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 457:87-91. 2009
    ..These findings have important implications for the development of next-generation T-cell-based vaccine candidates for HIV-1...
  4. ncbi Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials
    Eric Plennevaux
    Clinical Development Department, Sanofi Pasteur, Lyon, France
    Lancet 375:41-8. 2010
    ..from large clinical trials of paediatric, adult, and elderly people to find the appropriate antigen dose and vaccination schedule for the 2009 pandemic influenza A H1N1...
  5. ncbi Rapid cloning of high-affinity human monoclonal antibodies against influenza virus
    Jens Wrammert
    Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Nature 453:667-71. 2008
    ..Here we report that after booster vaccination there was a rapid and robust influenza-specific IgG+ antibody-secreting plasma cell (ASC) response that peaked ..
  6. ncbi Optimizing influenza vaccine distribution
    Jan Medlock
    Epidemiology and Public Health, Yale University School of Medicine, 60 College Street, New Haven, CT 06520 8034, USA
    Science 325:1705-8. 2009
    ..We find that optimal vaccination is achieved by prioritization of schoolchildren and adults aged 30 to 39 years...
  7. ncbi Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation
    Marc Baguelin
    Centre for Infections, Health Protection Agency, United Kingdom
    Vaccine 28:2370-84. 2010
    ..We present a real-time assessment of the effectiveness and cost-effectiveness of alternative influenza A/H1N1v vaccination strategies...
  8. ncbi Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong
    Benjamin J Cowling
    Infectious Disease Epidemiology Group, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China
    Clin Infect Dis 51:1370-9. 2010
    ..The relationship between seasonal influenza vaccine and susceptibility to 2009 pandemic A/H1N1 virus infection is not fully understood...
  9. ncbi Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses
    Denis Gaucher
    Laboratoire d Immunologie, Centre de Recherche du Centre Hospitalier de l Université de Montréal CR CHUM Saint Luc, Montreal, Quebec, Canada
    J Exp Med 205:3119-31. 2008
    ..to the yellow fever (YF) vaccine 17D (YF17D) in a cohort of 40 volunteers followed for up to 1 yr after vaccination. We show that immunization with YF17D leads to an integrated immune response that includes several effector ..
  10. ncbi Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial
    Xiao Feng Liang
    Chinese Center for Disease Control and Prevention, Beijing, China
    Lancet 375:56-66. 2010
    ..The current influenza pandemic calls for a safe and effective vaccine. We assessed the safety and immunogenicity of eight formulations of 2009 pandemic influenza A H1N1 vaccine produced by ten Chinese manufacturers...
  11. ncbi Induction of immunity to human immunodeficiency virus type-1 by vaccination
    M Juliana McElrath
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D3 100, Seattle, WA 98109, USA
    Immunity 33:542-54. 2010
    ....
  12. ncbi Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study
    Stefan Flasche
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
    PLoS Med 8:e1001017. 2011
    ....
  13. ncbi Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009
    Anthony E Fiore
    Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, GA 30333, USA
    MMWR Recomm Rep 58:1-52. 2009
    ..MMWR 2008;57[No. RR-7]). Information on vaccination issues related to the recently identified novel influenza A H1N1 virus will be published later in 2009...
  14. ncbi Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic
    Danuta M Skowronski
    BC Centre for Disease Control, Vancouver, BC
    CMAJ 182:1851-6. 2010
    ..We reassessed this profile of seroprotection by age in the same region six months after the fall 2009 pandemic and vaccination campaign.
  15. ncbi Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination
    Viggo F Van Tendeloo
    University of Antwerp, Faculty of Medicine, Vaccine and Infectious Disease Institute Vaxinfectio and Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Antwerp B 2650, Belgium
    Proc Natl Acad Sci U S A 107:13824-9. 2010
    ..Here, in a phase I/II trial, we investigated the effect of autologous dendritic cell vaccination in 10 patients with acute myeloid leukemia (AML)...
  16. ncbi Prime-boost vectored malaria vaccines: progress and prospects
    Adrian V S Hill
    The Jenner Institute, University of Oxford, Oxford, UK
    Hum Vaccin 6:78-83. 2010
    ..Such vectored vaccination regimes represent one of only two approaches that have induced repeatable partial efficacy in human P...
  17. ncbi Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial
    Zoltan Vajo
    University of Debrecen, Medical and Health Sciences Centre, Debrecen, Hungary
    Lancet 375:49-55. 2010
    ..We investigated the safety and immunogenicity of a whole-virion, inactivated, adjuvanted pandemic H1N1 vaccine in adult and elderly volunteers, given without or simultaneously with the 2009-10 seasonal trivalent influenza vaccine...
  18. ncbi Heterologous prime-boost vaccination
    Shan Lu
    China US Vaccine Research Center and Department of Infectious Diseases, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China
    Curr Opin Immunol 21:346-51. 2009
    ..Heterologous prime-boost represents a new way of immunization and will stimulate better understanding on the immunological basis of vaccines...
  19. ncbi Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas
    Clarisa B Palatnik-de-Sousa
    Department of General Microbiology, Institute of Microbiology Prof Paulo de Góes, Federal University of Rio de Janeiro UFRJ, Rio de Janeiro, RJ, Brazil
    Vaccine 27:3505-12. 2009
    ..We demonstrate here that vaccination with Leishmune does not interfere with the serological control campaign (110,000 dogs). Only 1...
  20. ncbi Population and risk group uptake of H1N1 influenza vaccine in mainland France 2009-2010: results of a national vaccination campaign
    Angie Bone
    Institut de veille sanitaire French Institute for Public Health Surveillance, 12 Rue du Val d Osne, 94415 Saint Maurice Cedex, France
    Vaccine 28:8157-61. 2010
    A mass vaccination campaign against influenza A/H1N1 was launched in France in October 2009. Vaccination was offered free of charge to the entire population according to a pre-defined order of priority...
  21. ncbi Future vaccination strategies against tuberculosis: thinking outside the box
    Stefan H E Kaufmann
    Department of Immunology, Max Planck Institute for Infection Biology, Chariteplatz 1, D 10117 Berlin, Germany
    Immunity 33:567-77. 2010
    ..Here, we review current and future strategies toward the rational design of novel vaccines against TB, as well as the progress made thus far, and the hurdles that need to be overcome in the near and distant future...
  22. ncbi Economic evaluation of human papillomavirus vaccination in the United Kingdom
    Mark Jit
    Modelling and Economics Unit, Centre for Infections, Health Protection Agency, London NW9 6BT
    BMJ 337:a769. 2008
    To assess the cost effectiveness of routine vaccination of 12 year old schoolgirls against human papillomavirus infection in the United Kingdom.
  23. ncbi Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination
    Bruna C G de Alencar
    Centro Interdisciplinar de Terapia Gênica CINTERGEN, Universidade Federal de Sao Paulo Escola Paulista de Medicina, Rua Mirassol 207, Sao Paulo, SP 04044 010, Brazil
    Infect Immun 77:4383-95. 2009
    ..Our study thus demonstrated a role for perforin and IFN-gamma in a number of T-cell-mediated effector functions and in the antiparasitic immunity generated by a heterologous plasmid DNA prime-adenovirus boost vaccination strategy.
  24. ncbi Vaccines and vaccination strategies against human cutaneous leishmaniasis
    Ifeoma Okwor
    Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, CA
    Hum Vaccin 5:291-301. 2009
    ..However, there is as yet no effective vaccine against the disease in humans. Although vaccination in murine studies has yielded promising results, these vaccines have failed miserably when tested in primates ..
  25. ncbi Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans
    Troy D Querec
    Emory Vaccine Center, Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, Georgia 30329, USA
    Nat Immunol 10:116-25. 2009
    ..b>Vaccination induced genes that regulate virus innate sensing and type I interferon production...
  26. ncbi High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model
    Sheetij Dutta
    Department of Epitope Mapping, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America
    PLoS ONE 4:e8138. 2009
    ..High titers of cross-strain inhibitory antibodies against AMA1 are therefore critical to confer solid protection, and the Aotus model can be used to down-select future AMA1 formulations, prior to advanced human trials...
  27. ncbi Viruses as vaccine vectors for infectious diseases and cancer
    Simon J Draper
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK
    Nat Rev Microbiol 8:62-73. 2010
    ....
  28. ncbi Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1
    Adel Benlahrech
    Department of Immunology, Imperial College London, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, United Kingdom
    Proc Natl Acad Sci U S A 106:19940-5. 2009
    ..individuals that were seropositive for adenovirus serotype 5 (Ad5) showed increased rates of HIV-1 infection on vaccination with an Ad5 vaccine...
  29. ncbi Report from a WHO Working Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae
    Hanna Nohynek
    Pediatr Infect Dis J 22:e1-11. 2003
    ..The intention is to allow more meaningful comparisons of study results from conjugate pneumococcal vaccine trials...
  30. ncbi Economic value of seasonal and pandemic influenza vaccination during pregnancy
    Richard H Beigi
    Division of Reproductive Infectious Diseases, Department of Obstetrics, Gynecology and Reproductive Sciences, Magee Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA
    Clin Infect Dis 49:1784-92. 2009
    ..The study objective was to evaluate the cost-effectiveness of maternal influenza vaccination using both single- and 2-dose strategies against laboratory-confirmed influenza secondary to both seasonal ..
  31. ncbi Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus
    Hiroyuki Kayamuro
    Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, 7 6 8 Saito Asagi, Ibaraki, Osaka 567 0085, Japan
    J Virol 84:12703-12. 2010
    ..In summary, our results demonstrate that IL-1 family cytokines are potential mucosal vaccine adjuvants and can induce Ag-specific immune responses for protection against pathogens like influenza virus...
  32. ncbi BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination
    Laurent Derre
    Ludwig Institute for Cancer Research, Hopital Orthopedique, Niveau 5 Est, Av Pierre Decker 4, Lausanne, Switzerland
    J Clin Invest 120:157-67. 2010
    ..CD8+ T cells from melanoma patients with spontaneous antitumor immune responses and after conventional peptide vaccination. Remarkably, addition of CpG oligodeoxynucleotides to the vaccine formulation led to progressive downregulation ..
  33. ncbi Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination
    Victoria R Polonis
    Walter Reed Army Institute of Research, Washington, DC, USA
    Virology 375:315-20. 2008
    ....
  34. ncbi Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector
    Andrew T Catanzaro
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-3017, USA
    J Infect Dis 194:1638-49. 2006
    ..This multiclade rAd5 HIV-1 vaccine is now being evaluated in combination with a multiclade HIV-1 DNA plasmid vaccine...
  35. ncbi Influenza vaccine coverage rates and perceptions on vaccination in South Korea
    Sae Yoon Kee
    Division of Infectious Diseases, Department of Internal Medicine, Korea University Medical College, 97 Gurodonggil, Gurodong, Gurogu, Seoul, Republic of Korea
    J Infect 55:273-81. 2007
    This survey was performed to assess the level of influenza vaccine coverage, to understand the driving forces and barriers to vaccination and determine vaccination interventions for the following year in Korean population.
  36. ncbi High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma
    Jochen Greiner
    Department of Internal Medicine III, University of Ulm, Albert Einstein Allee 23 89081 Ulm, Germany
    Haematologica 95:1191-7. 2010
    ..To improve the outcome of the vaccine, a second cohort was vaccinated with a higher dose of 1,000 microg peptide...
  37. ncbi Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi
    Paula Ordonhez Rigato
    CTCMol, UNIFESP, Escola Paulista de Medicina, Rua Mirassol 207, Sao Paulo, SP, Brazil 04044 010
    Infect Immun 79:2120-30. 2011
    ..From these results, we concluded that heterologous plasmid DNA prime-adenovirus boost vaccination generated a stable pool of functional protective long-lived CD8(+) T cells with an effector memory phenotype.
  38. ncbi Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination
    Stephanie A Freel
    Duke University Human Vaccine Institute, Departments of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 84:4998-5006. 2010
    Control of HIV-1 replication following nonsterilizing HIV-1 vaccination could be achieved by vaccine-elicited CD8(+) T-cell-mediated antiviral activity...
  39. ncbi Blood-stage malaria vaccines - recent progress and future challenges
    A L Goodman
    The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK
    Ann Trop Med Parasitol 104:189-211. 2010
    ..The future challenges that face this field of vaccine research are also described...
  40. ncbi Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1
    Robert M Paris
    US Military HIV Research Program MHRP, Department of Retrovirology, Armed Forces Research Institute of Medical Sciences, 315 6 Rajvithi Road, Bangkok, 10400, Thailand
    Expert Rev Vaccines 9:1055-69. 2010
    ....
  41. ncbi Immunological mechanisms of vaccination
    Bali Pulendran
    Emory Vaccine Center at Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA
    Nat Immunol 12:509-17. 2011
    ..Here we will discuss these advances and emerging themes on the immunology of vaccination.
  42. ncbi Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma
    H Schori
    Department of Neurobiology, The Weizmann Institute of Science, Rehovot 76100, Israel
    Proc Natl Acad Sci U S A 98:3398-403. 2001
    ....
  43. ncbi Current status of vaccines for schistosomiasis
    Donald P McManus
    Molecular Parasitology Laboratory, Queensland Institute of Medical Research, 300 Herston Road, Brisbane Q4006, Australia
    Clin Microbiol Rev 21:225-42. 2008
    ..haematobium) and Asian (S. japonicum) schistosomes is then discussed, as are new approaches that may improve the efficacy of available vaccines and aid in the identification of new targets for immune attack...
  44. ncbi Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis
    Andrea Cruz
    Life and Health Sciences Research Institute, School of Health Sciences, University of Minho, 4710 057 Braga, Portugal
    J Exp Med 207:1609-16. 2010
    ..a model wherein mice are vaccinated with bacille Calmette-Guérin after Mtb infection, we show that repeated vaccination results in increased IL-17, tumor necrosis factor, IL-6, and MIP-2 expression, influx of granulocytes/..
  45. ncbi Harnessing invariant NKT cells in vaccination strategies
    Vincenzo Cerundolo
    Tumour Immunology Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DU, UK
    Nat Rev Immunol 9:28-38. 2009
    To optimize vaccination strategies, it is important to use protocols that can 'jump-start' immune responses by harnessing cells of the innate immune system to assist the expansion of antigen-specific B and T cells...
  46. ncbi Influence of Mycobacterium bovis BCG vaccination on cellular immune response of guinea pigs challenged with Mycobacterium tuberculosis
    Diane Ordway
    Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523 1682, USA
    Clin Vaccine Immunol 15:1248-58. 2008
    ..Whereas BCG vaccination reduced the influx of heterophils (neutrophils) into the lungs, an early B-cell influx was observed in these ..
  47. ncbi Baculovirus-based vaccination vectors allow for efficient induction of immune responses against plasmodium falciparum circumsporozoite protein
    Robert Strauss
    Department of Medicine, Division of Medical Genetics, University of Washington, Seattle, Washington, USA
    Mol Ther 15:193-202. 2007
    ..In this study, we evaluated the potential of baculovirus vectors for malaria vaccination. To induce efficient CD4(+) and CD8(+) T-cell responses, we produced a series of vectors that display the ..
  48. ncbi Seroprevalence of antibodies to pandemic (H1N1) 2009 influenza virus among hospital staff in a medical center in Taiwan
    Yu Jiun Chan
    Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
    J Chin Med Assoc 73:62-6. 2010
    ..In addition to specific antiviral agents, massive vaccination is thought to be the most effective way of controlling the transmission...
  49. ncbi Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model
    Akihiro Mouri
    Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsuruma cho, Showa Ku, Nagoya 466 8560, Japan
    FASEB J 21:2135-48. 2007
    ..Taken together, these results suggest that immunotherapy with AAV/Abeta is a safe and effective treatment for AD...
  50. ncbi A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles
    Pratip K Chattopadhyay
    Immunotechnology Section, Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, 40 Convent Drive, Room 5509, Bethesda, Maryland 20892, USA
    Nat Med 11:1113-7. 2005
    ..For vaccine- or pathogen-specific responses, we found substantial heterogeneity in expression of CD154 and cytokines, suggesting previously unrecognized diversity in abilities of responding cells to stimulate APCs through CD40...
  51. ncbi Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches
    Sun Young Kim
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
    Pharmacoeconomics 26:191-215. 2008
    ..effectiveness, taking into account the relevant biological, clinical, epidemiological and economic factors of a vaccination programme, generally requires use of a model...
  52. ncbi Proteome-wide analysis of the serological response to vaccinia and smallpox
    D Huw Davies
    Center for Virus Research, University of California, Irvine, CA 92697, USA
    Proteomics 7:1678-86. 2007
    The eradication of smallpox by vaccination with vaccinia virus was probably one of the greatest achievements of vaccinology. However, the immunological basis of this protection is not fully understood...
  53. ncbi Vaccination and the theory of games
    Chris T Bauch
    Department of Mathematics and Statistics, University of Guelph, Guelph, ON, Canada N1G 2W1
    Proc Natl Acad Sci U S A 101:13391-4. 2004
    Voluntary vaccination policies for childhood diseases present parents with a subtle challenge: if a sufficient proportion of the population is already immune, either naturally or by vaccination, then even the slightest risk associated ..
  54. ncbi Systematic review of qualitative studies exploring parental beliefs and attitudes toward childhood vaccination identifies common barriers to vaccination
    Edward Mills
    University of Oxford, UK
    J Clin Epidemiol 58:1081-8. 2005
    ..studies can lead to identification of consistent themes across studies, using barriers toward childhood vaccination as an example...
  55. ncbi Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles
    Jae Min Song
    Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA
    Antiviral Res 88:244-7. 2010
    To develop a more effective vaccination method against H5N1 virus, we investigated the immunogenicity and protective efficacy after skin vaccination using microneedles coated with influenza virus-like particles containing hemagglutinin ..
  56. ncbi Dissolving polymer microneedle patches for influenza vaccination
    Sean P Sullivan
    Wallace H Coulter Department of Biomedical Engineering, Emory University, Atlanta, Georgia, USA
    Nat Med 16:915-20. 2010
    Influenza prophylaxis would benefit from a vaccination method enabling simplified logistics and improved immunogenicity without the dangers posed by hypodermic needles...
  57. ncbi Reduction of Coxiella burnetii prevalence by vaccination of goats and sheep, The Netherlands
    Lenny Hogerwerf
    Department of Farm Animal Health, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
    Emerg Infect Dis 17:379-86. 2011
    ..We identified the effect of vaccination on bacterial shedding by small ruminants...
  58. ncbi Delaying bacillus Calmette-Guérin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age
    Sarah Burl
    Medical Research Council United Kingdom, The Gambia, Fajara, The Gambia, West Africa
    J Immunol 185:2620-8. 2010
    ..Gambian neonates were recruited at birth and randomized to receive BCG vaccination either at birth or at 4 1/2 mo. Mycobacterial immune responses were assessed at birth, 4 1/2, and 9 mo of age...
  59. ncbi Systems biology of vaccination for seasonal influenza in humans
    Helder I Nakaya
    Emory Vaccine Center, Emory University, Atlanta, Georgia, USA
    Nat Immunol 12:786-95. 2011
    Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons...
  60. ncbi Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis
    P C Melby
    Medical Service, Department of Veterans Affairs Medical Center, South Texas Veterans Health Care System, University of Texas Health Science Center, San Antonio, Texas 78229 3900, USA
    Infect Immun 69:4719-25. 2001
    ..following subclinical or resolved infection with the intracellular parasite Leishmania donovani suggests that vaccination could prevent visceral leishmaniasis (VL)...
  61. ncbi Perceived seriousness of seasonal and A(H1N1) influenzas, attitudes toward vaccination, and vaccine uptake among U.S. adults: does the source of information matter?
    Jurgen Maurer
    RAND Corporation, Arlington, VA 22202, USA
    Prev Med 51:185-7. 2010
    ..and assessed their perceptions of the seriousness of both types of influenza and corresponding attitudes toward vaccination during the 2009-2010 influenza season...
  62. ncbi Influenza vaccination and intention to receive the pandemic H1N1 influenza vaccine among healthcare workers of British Columbia, Canada: a cross-sectional study
    Fariba Kaboli
    Disease Prevention, Vancouver, British Columbia, Canada
    Infect Control Hosp Epidemiol 31:1017-24. 2010
    To assess healthcare workers' attitudes and concerns regarding seasonal and pandemic influenza vaccines in order to improve vaccination campaign communications.
  63. ncbi Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia
    Peter G Maslak
    Leukemia Service, Department of Medicine, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Blood 116:171-9. 2010
    ..Three patients developed a delayed hypersensitivity reaction after vaccination. Definite related toxicities were minimal...
  64. ncbi Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study
    Isabel Leroux-Roels
    Center for Vaccinology, Ghent University and Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    Vaccine 28:849-57. 2010
    ..play a key role in pandemic mitigation by promoting a rapid immune response to infection and/or subsequent vaccination with strains drifted from the primary vaccine strain...
  65. ncbi Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696
    John M Kirkwood
    Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213 2584, USA
    Clin Cancer Res 15:1443-51. 2009
    ....
  66. ncbi The dynamics of measles in sub-Saharan Africa
    Matthew J Ferrari
    Center for Infectious Disease Dynamics, The Pennsylvania State University, University Park, Pennsylvania 16802, USA
    Nature 451:679-84. 2008
    Although vaccination has almost eliminated measles in parts of the world, the disease remains a major killer in some high birth rate countries of the Sahel...
  67. ncbi Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study
    Loretta Brabin
    Academic Unit of Obstetrics and Gynaecology, St Mary s Hospital, University of Manchester, Manchester M13 OJH
    BMJ 336:1056-8. 2008
    ..To assess the feasibility and acceptability of delivering a human papillomavirus (HPV) vaccine to adolescent girls...
  68. ncbi Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques
    Lauren A Hirao
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 422 Curie Boulevard, 505 SCL, Philadelphia, PA 19104, United States
    Vaccine 26:3112-20. 2008
    ..These data suggest that adjuvant and improved delivery methods may be able to overcome previous immunogenicity limitations in DNA vaccine technology...
  69. ncbi Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial
    Pedro Aide
    Centro de Investigação em Saúde da Manhiça, Maputo, Mozambique
    PLoS ONE 5:e13838. 2010
    ..The RTS,S/AS02(D) vaccine has been shown to have a promising safety profile, to be immunogenic and to confer protection against malaria in children and infants...
  70. ncbi Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge
    Joseph J Mattapallil
    Vaccine Research Center, National Institute of Allergy and Infectious Disease (NIAID, National Institutes of Health (NIH, Bethesda, MD 20892, USA
    J Exp Med 203:1533-41. 2006
    ..Here, we demonstrate that prior vaccination reduces this destruction during acute SIV Mac251 infection, leading to better survival and long-term outcome...
  71. ncbi Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy
    Jane J Kim
    Department of Health Policy and Management, Program in Health Decision Science, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
    Vaccine 26:4015-24. 2008
    ..With 70% vaccination and screening coverage, lifetime risk of cancer was reduced by 20.4-76...
  72. ncbi Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India
    M Diaz
    Unit of Infections and Cancer UNIC, Cancer Epidemiology Research Programme, Catalan Institute of Oncology ICO, Av Gran Via, s n km 2 7, 08907 L Hospitalet de Llobregat, Barcelona, Spain
    Br J Cancer 99:230-8. 2008
    ..and calculated incremental cost-effectiveness ratios (I$/YLS) for the following strategies: pre-adolescent vaccination of girls before age 12, screening of women over age 30, and combined vaccination and screening...
  73. ncbi Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus
    Yuan Fang
    Division of Immunology, International Institute of Infection and Immunity, Shantou University Medical College, 22 Xinling Road, Shantou, Guangdong 515041, People s Republic of China
    J Virol 84:8369-88. 2010
    ..Taken together, our results better characterize the specific molecular pathways leading to adjuvant activity in different adjuvant-mediated influenza virus vaccinations...
  74. ncbi Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra
    Keith S Reisinger
    Primary Physicians Research, Pittsburgh, PA 15241, USA
    Clin Vaccine Immunol 16:1810-5. 2009
    ..The hSBA titers following vaccination with MenACWY-CRM and Menactra were compared in noninferiority and prespecified superiority analyses...
  75. ncbi Extralymphoid CD8+ T cells resident in tissue from simian immunodeficiency virus SIVmac239{Delta}nef-vaccinated macaques suppress SIVmac239 replication ex vivo
    Justin M Greene
    Department of Pathology and Laboratory Medicine, University of Wisconsin Madison, 585 Science Drive, Madison, WI 53711, USA
    J Virol 84:3362-72. 2010
    Live-attenuated vaccination with simian immunodeficiency virus (SIV) SIVmac239Deltanef is the most successful vaccine product tested to date in macaques...
  76. ncbi Influenza vaccination and mortality: differentiating vaccine effects from bias
    Bruce Fireman
    Kaiser Permanente, 2000 Broadway, Oakland, CA 94612, USA
    Am J Epidemiol 170:650-6. 2009
    It is widely believed that influenza (flu) vaccination of the elderly reduces all-cause mortality, yet randomized trials for assessing vaccine effectiveness are not feasible and the observational research has been controversial...
  77. ncbi Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species
    Lisa E Hensley
    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA
    PLoS Pathog 6:e1000904. 2010
    ....
  78. ncbi Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A
    Simone C de Cassan
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, United Kingdom
    Clin Vaccine Immunol 17:1066-73. 2010
    ..to the containment of the epidemic, it is likely that elimination of the disease can only be achieved through vaccination. Vaccine-induced protection from Mycobacterium tuberculosis is dependent, at least in part, on a robust Th1 ..
  79. ncbi QTL for traits related to humoral immune response estimated from data of a porcine F2 resource population
    K Wimmers
    Research Institute for the Biology of Farm Animals FBN, Research Unit Molecular Biology, Dummerstorf, Germany
    Int J Immunogenet 36:141-51. 2009
    ..disease virus (Suid herpesvirus I, SuHVI) and porcine reproductive and respiratory syndrome virus (PRRSV) vaccination at 6, 14 and 16 weeks of age. Animals were genotyped at 88 autosomal markers...
  80. ncbi Enhancement of antigen-specific Treg vaccination in vivo
    Carolin Daniel
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 107:16246-51. 2010
    ..feasible to achieve highly effective antigen-driven conversion of naive T cells into Treg and their expansion in vivo and thereby the described protocols constitute important tools to achieve immunological tolerance by Treg vaccination.
  81. ncbi Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus
    Rogier Bodewes
    Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands
    PLoS ONE 4:e5538. 2009
    Annual vaccination against seasonal influenza viruses is recommended for certain individuals that have a high risk for complications resulting from infection with these viruses...
  82. ncbi Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels
    Grazia Galli
    Research Center, Novartis Vaccines and Diagnostics, Via Fiorentina 1, Siena 53100, Italy
    Proc Natl Acad Sci U S A 106:3877-82. 2009
    Immune responses to vaccination are tested in clinical trials. This process usually requires years especially when immune memory and persistence are analyzed...
  83. ncbi Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines
    Andrew J Pollard
    Department of Paediatrics, University of Oxford, Level 2, Children s Hospital, Oxford, UK
    Nat Rev Immunol 9:213-20. 2009
    ..In this Science and Society article, we describe how vaccine-induced immunity wanes rapidly after vaccination in early childhood and argue that strategies that sustain protection in the population must be considered.
  84. ncbi Novel prophylactic and therapeutic vaccine against tuberculosis
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone, Kitaku, Sakai, Osaka 591 8555, Japan
    Vaccine 27:3267-70. 2009
    ..These data indicate that our novel DNA vaccine might be useful against Mycobacterium tuberculosis including XDR-TB and MDR-TB for human therapeutic clinical trials...
  85. ncbi Modelling the seasonality of rotavirus disease and the impact of vaccination in England and Wales
    Christina Atchison
    Infectious Diseases Epidemiology Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
    Vaccine 28:3118-26. 2010
    ..age-structured model of rotavirus transmission and disease to investigate the population-level effects of vaccination in England and Wales...
  86. ncbi Impact of electronic health record-based alerts on influenza vaccination for children with asthma
    Alexander G Fiks
    Pediatric Generalist Research Group, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Pediatrics 124:159-69. 2009
    The goal was to assess the impact of influenza vaccine clinical alerts on missed opportunities for vaccination and on overall influenza immunization rates for children and adolescents with asthma.
  87. ncbi Preparing for HPV vaccination in South Africa: key challenges and opinions
    Jane Harries
    Women s Health Research Unit, School of Public Health and Family Medicine, University of Cape Town, South Africa
    Vaccine 27:38-44. 2009
    ..The optimal target populations for HPV vaccination was influenced by the perceived median age of sexual activity in South African girls (9-15 years), with an ..
  88. ncbi Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete
    William P Hanage
    Department of Infectious Disease Epidemiology, Imperial College London, London, UK
    Epidemics 2:80-4. 2010
    Invasive pneumococcal disease (IPD) has been reduced in the US following conjugate vaccination (PCV7) targeting seven pneumococcal serotypes in 2000. However, increases in IPD due to other serotypes have been observed, in particular 19A...
  89. ncbi Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization
    Chun Chao
    Department of Research and Evaluation, Kaiser Permanente Southern California, 100 S Los Robles, 2nd Floor, Pasadena, CA 91101, USA
    Am J Epidemiol 171:357-67. 2010
    ..Female members of Kaiser Permanente Southern California aged 9-26 years were identified and assessed for HPV vaccination between October 2006 and March 2008...
  90. ncbi Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge
    Gretchen S Jimenez
    Vical Incorporated, San Diego, California 92121, USA
    Hum Vaccin 3:157-64. 2007
    ..Vaxfectin adjuvanticity was confirmed with a low dose of HA pDNA. These promising proof-of-concept data support the clinical development of Vaxfectin-formulated pDNA encoding NP + M2 consensus proteins...
  91. ncbi Immunogenicity of plasmids encoding P12A and 3C of FMDV and swine IL-18
    Ma Mingxiao
    Genetic Engineering Laboratory, Academy of Military Medical Sciences, Changchun 130062, PR China
    Antiviral Res 76:59-67. 2007
    ..Mice and swine were given booster vaccination twice and once, respectively, and swine were challenged 10 days after the booster vaccination...
  92. ncbi Alternative early life vaccination programs for companion animals
    H Poulet
    Merial Research and Development, 254 rue Marcel Merieux, 69007 Lyon, France
    J Comp Pathol 137:S67-71. 2007
    An experimental challenge study of multicomponent vaccination of kittens is reported...
  93. ncbi Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1
    Stephen Mark Tompkins
    Food and Drug Administration, Bethesda, Maryland, USA
    Emerg Infect Dis 13:426-35. 2007
    ..This vaccination induced antibodies that cross-reacted with divergent M2 peptide from an H5N1 subtype...
  94. ncbi Enhanced protective efficacy and reduced viral load of foot-and-mouth disease DNA vaccine with co-stimulatory molecules as the molecular adjuvants
    Chong Xiao
    State Key Laboratory for Agro Biotechnology and the Key Laboratory of Agro Microbial Resources and Applications of MOA, China Agricultural University, Beijing 100094, China
    Antiviral Res 76:11-20. 2007
    To improve efficacy of DNA vaccination, various approaches have been developed, including the use of plasmid expressing co-stimulatory molecules as molecular adjuvants...
  95. ncbi Complete protection of mice against a lethal dose challenge of western equine encephalitis virus after immunization with an adenovirus-vectored vaccine
    Josh Q H Wu
    Chemical and Biological Defence Section, Defence Research and Development Canada Suffield, Box 4000, Station Main, Medicine Hat, Alberta, Canada
    Vaccine 25:4368-75. 2007
    ..In addition, we showed that passive transfer of serum from the Ad5-WEEV-immunized mice could partially control WEEV infection. These results demonstrate that HAd5 vectors are promising for WEEV vaccine development...
  96. ncbi Protection of mice from H5N1 influenza challenge by prophylactic DNA vaccination using particle mediated epidermal delivery
    Michaela Sharpe
    PowderMed Ltd, 4 Robert Robinson Avenue, Oxford Science Park, Oxford OX4 4GA, UK
    Vaccine 25:6392-8. 2007
    ..b>Vaccination led to potent anti-HA serological responses that were significantly enhanced by the inclusion of a plasmid ..
  97. ncbi Immunogenicity of porcine circovirus type 2 capsid protein targeting to different subcellular compartments
    Huiying Fan
    Laboratory of Animal Virology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, Hubei, PR China
    Mol Immunol 45:653-60. 2008
    ..IFN-gamma, can enhance the replication of PCV2, indicating that the high levels of IFN-gamma induced by DNA vaccination seem to have potential deleterious effect on protective immunity...
  98. ncbi Field effectiveness of vaccination against tick-borne encephalitis
    Franz X Heinz
    Institute of Virology, Medical University of Vienna, Kinderspitalgasse 15, AT 1095 Vienna, Austria
    Vaccine 25:7559-67. 2007
    ..In Europe, highly purified formalin-inactivated whole virus vaccines are in widespread use, but the vaccination coverage differs significantly between countries with TBE endemicity...
  99. ncbi [A special immunization clinic tailors vaccinations]
    Bernice Aronsson
    Sachsska barnsjukhuset, , Stockholm
    Lakartidningen 105:1675-9. 2008
  100. ncbi A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses
    Mary A Hoelscher
    Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Infect Dis 197:1185-8. 2008
    ..We developed an adenoviral vector-based vaccine that contains hemagglutinin protein from clade 1 and clade 2 viruses, as well as conserved nucleoprotein, to broaden the vaccine coverage against H5N1 viruses...
  101. ncbi Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1
    W Ripley Ballou
    Clinical Development, MedImmune, Gaithersburg, Maryland 20878, USA
    J Infect Dis 187:675-8. 2003
    ..5 or 25 microg MEDI-491 at 0, 1, and 6 months. MEDI-491 was safe and immunogenic. All volunteers developed neutralizing antibody titers that peaked after the third immunization and were sustained through study day 364...

Research Grants101 found, 100 shown here

  1. Role of cyclooxygenase-2 in antibody responses to vaccination
    Richard Phipps; Fiscal Year: 2007
    Optimal humoral (i.e. antibody) responses to vaccination are essential if humans are to be protected against potentially devastating infectious agents. These include viruses such as variola that cause smallpox...
  2. VARIABLE GENE USE AND PNEUMOCOCCAL IMMUNITY IN AIDS
    Liise Anne Pirofski; Fiscal Year: 2004
    ..This emergence of antibiotic resistant pneumococcus has increased the need for vaccination of high-risk groups such as HIV+ persons...
  3. Recommendation of HPV Vaccination among U.S. Physicians
    Susan Vadaparampil; Fiscal Year: 2009
    ..The ACIP recommendation also allows for vaccination of girls beginning at age nine as well as catch-up vaccination of girls and women 13-26 years of age...
  4. Recommendation of HPV Vaccination among U.S. Physicians
    Susan T Vadaparampil; Fiscal Year: 2010
    ..The ACIP recommendation also allows for vaccination of girls beginning at age nine as well as catch-up vaccination of girls and women 13-26 years of age...
  5. Anti-Idiotype Therapy of Human B Cell Malignancy
    Ronald Levy; Fiscal Year: 2007
    ..Animal models of B cell lymphoma will be used to develop more powerful methods of vaccination against the idiotype and to study the mechanisms of tumor immunity...
  6. Health Promotion Coaching/Vaccine for Homeless Parolees
    Adeline M Nyamathi; Fiscal Year: 2010
    ..advice from our community partners who have successfully treated parolees and our experience with hepatitis vaccination work, we propose to conduct a prospective, three-group study that randomly assigns 700 ready-for- discharge ..
  7. Health Promotion Coaching/Vaccine for Homeless Parolees
    Adeline Nyamathi; Fiscal Year: 2009
    ..advice from our community partners who have successfully treated parolees and our experience with hepatitis vaccination work, we propose to conduct a prospective, three-group study that randomly assigns 700 ready-for- discharge ..
  8. Health Promotion Coaching/Vaccine for Homeless Parolees
    Adeline M Nyamathi; Fiscal Year: 2010
    ..advice from our community partners who have successfully treated parolees and our experience with hepatitis vaccination work, we propose to conduct a prospective, three-group study that randomly assigns 700 ready-for- discharge ..
  9. HIFU-enhanced tumor vaccines
    Chandan Guha; Fiscal Year: 2010
    ..HIFU would be used to ablate the local tumor and release tumor-derived HSPs and peptides for an in situ auto-vaccination. In a recently completed phase I SBIR proposal (PI, Naren Sanghvi, Focus Surgery), we demonstrated that cycles ..
  10. HIFU-enhanced tumor vaccines
    Chandan Guha; Fiscal Year: 2010
    ..HIFU would be used to ablate the local tumor and release tumor-derived HSPs and peptides for an in situ auto-vaccination. In a recently completed phase I SBIR proposal (PI, Naren Sanghvi, Focus Surgery), we demonstrated that cycles ..
  11. A Phase I Study to Evaluate the Safety and Immunogenicity of HPV 16 L2 11-200
    WARNER KING HUH; Fiscal Year: 2010
    ..The two HPV capsid proteins, L1 and L2, are both independent protective antigens. Vaccination with HPV L1 virus-like particles (VLP) induces neutralizing antibodies and protection in patients with strong ..
  12. TNF family members for lymph angiogenesis and lymph node hypertrophy
    Yang Xin Fu; Fiscal Year: 2010
    ..venules (HEV) in peripheral tissues leads to hypertrophy of draining lymph nodes (LN) during inflammation/vaccination, but the molecular mechanism regulating LN hypertrophy is poorly understood...
  13. Stable Micronized Vaccines Against Smallpox and Japanese Encephalitis
    VICTOR BRONSHTEIN; Fiscal Year: 2007
    ..the existence of variola stockpiles and the threat of bioterrorism demand that immunity to smallpox through vaccination be maintained...
  14. Oral Vaccination for AIDS Prevention in Rhesus Macaques
    Anna Aldovini; Fiscal Year: 2010
    ..We have established vaccination regimens that stimulate mucosal responses with an SIV DNA vaccine, which consists of a single plasmid carrying ..
  15. Optimization of Tumor Vaccines for the Aged
    Joseph Lustgarten; Fiscal Year: 2011
    ..Our preliminary results indicate that treatment with intratumoral injections of CpG-ODN plus peptide vaccination and depletion of Tregs induce an immune response that reject the primary tumors in 100% of young A2xneu mice ..
  16. HBV Prevention for Homeless At-Risk for HBV/HCV/HIV
    Adeline Nyamathi; Fiscal Year: 2007
    ..Thus, education and screening programs for HAV, HBV, HCV, and HW, combined with vaccination programs for HAV and HBV, can significantly decrease Hepatitis-related morbidity and mortality...
  17. Minor Histocompatilibity Vaccination After Allo-Transpl*
    Koen Van Besien; Fiscal Year: 2004
    ..We hypothesize that post-transplant vaccination with HA1 or HA2 peptides in combination with GM-CSF in donor-recipient pairs that are HLA-identical, but ..
  18. Empirical space-time evaluation of priority groups for influenza control
    John Brownstein; Fiscal Year: 2007
    b>Vaccination against influenza is the mainstay of prevention efforts and was initially targeted at older individuals and those with high risk of complications...
  19. MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES
    Craig Slingluff; Fiscal Year: 2009
    The classic paradigm for understanding the immunobiology of cutaneous vaccination is that antigen delivered with an adjuvant creates an inflammatory stimulus, which in turn induces epidermal Langerhans cells to mature and to migrate to ..
  20. MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES
    CRAIG LEE SLINGLUFF; Fiscal Year: 2010
    The classic paradigm for understanding the immunobiology of cutaneous vaccination is that antigen delivered with an adjuvant creates an inflammatory stimulus, which in turn induces epidermal Langerhans cells to mature and to migrate to ..
  21. Poxvirus adverse effects on cardiac cells and the heart
    Barbara Sherry; Fiscal Year: 2005
    ..bioterrorists may release smallpox virus in the United States, the government has implemented a multi-stage vaccination program...
  22. HBV Prevention for Homeless at Risk for HBV/HCV/HIV
    Adeline M Nyamathi; Fiscal Year: 2010
    ..RO1 award has enabled us to implement a successful intervention designed to evaluate the effectiveness of a HBV vaccination intervention with homeless adults...
  23. HBV Prevention for Homeless at Risk for HBV/HCV/HIV
    Adeline Nyamathi; Fiscal Year: 2009
    ..RO1 award has enabled us to implement a successful intervention designed to evaluate the effectiveness of a HBV vaccination intervention with homeless adults...
  24. HBV Prevention for Homeless at Risk for HBV/HCV/HIV
    Adeline Nyamathi; Fiscal Year: 2009
    ..RO1 award has enabled us to implement a successful intervention designed to evaluate the effectiveness of a HBV vaccination intervention with homeless adults...
  25. Risk Factors for Eczema Vaccinatum in Atopic Dermatitis
    Peter Elias; Fiscal Year: 2005
    ..that smallpox virus might be employed as a bioterrorism agent has led to an early implementation of a limited vaccination program...
  26. Risk Factors for Eczema Vaccinatum in Atopic Dermatitis
    Walter Holleran; Fiscal Year: 2009
    ..that smallpox virus might be employed as a bioterrorism agent has led to an early implementation of a limited vaccination program...
  27. Risk Factors for Eczema Vaccinatum in Atopic Dermatitis
    Walter Holleran; Fiscal Year: 2007
    ..that smallpox virus might be employed as a bioterrorism agent has led to an early implementation of a limited vaccination program...
  28. Development of Breast Cancer Vaccines
    Wei Zen Wei; Fiscal Year: 2010
    ..We will test the hypothesis that vaccination with Her-2-neu hybrid DNA vaccine will reject established tumors and prevent tumor metastasis...
  29. Innate Effectors of rAls3p-N Anti-Candida Vaccine
    Brad J Spellberg; Fiscal Year: 2010
    ..We have also found that: 1) antibody titers d Als3p (rAls3p-N). We have found that vaccination of mice with r a vaccine to prevent life threatening Candida i Furthermore, infections caused by strains and ..
  30. Innate Effectors of rAls3p-N Anti-Candida Vaccine
    Brad Spellberg; Fiscal Year: 2009
    ..We have also found that: 1) antibody titers d Als3p (rAls3p-N). We have found that vaccination of mice with r a vaccine to prevent life threatening Candida i Furthermore, infections caused by strains and ..